“Susannah brings a breadth and depth of strategic and operational
experience to Tricida that we believe will enable us to build a
fine-tuned commercial organization focused on delivering a
first-in-class potential therapy to not only treat metabolic acidosis
but potentially slow the progression of chronic kidney disease (CKD),”
said Gerrit Klaerner, Ph.D., Tricida’s Chief Executive Officer,
President and Board Member.

Dr. Cantrell has over 20 years of commercial industry experience across
sales, operations, marketing and global commercial strategy with
therapeutic experience in cell therapy, oncology, inflammation,
anti-infectives, cardiology, neurology and endocrinology. She most
recently served as Vice President & Head, Global Commercial Strategy and
Marketing Oncology at Gilead Sciences, Inc. where she has been
instrumental in leading and building its oncology business franchise
from 2011 to present. While at Gilead, she led global marketing for
YESCARTA, ZYDELIG and pre-launch activities for andecaliximab and the
company’s B-Cell portfolio. Prior to her time at Gilead, Dr. Cantrell
held various senior level positions at Genentech/Roche from 2005 to
2011, including marketing, strategic business planning and sales. She
participated in life-cycle management and the pre-launch and commercial
launch of several products, including RITUXAN, HERCEPTIN, AVASTIN and
TARCEVA. Dr. Cantrell also led the pre-launch and commercialization
activities for Genentech’s BioOncology pipeline. Prior to Genentech, Dr.
Cantrell held sales and marketing positions at GlaxoSmithKline, where
she managed the anti-infective portfolio, including the AUGMENTIN,
TIMENTIN and BACTROBAN. Dr. Cantrell holds a BA in biology from
Westminster College and a PhD in biochemistry from the University of
Missouri-Columbia.

“I am excited to join Tricida and to advance the pre-launch planning and
strategic commercial efforts for TRC101 that are already underway,” said
Dr. Cantrell. “I believe that TRC101 has the potential to transform the
treatment of patients with metabolic acidosis and CKD. I look forward to
working with the Tricida team on the continued development and potential
commercialization of this important product candidate.”

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and
commercialization of TRC101, a non-absorbed, orally-administered polymer
designed to treat metabolic acidosis in patients with CKD. Metabolic
acidosis is a condition commonly caused by CKD that has been shown to
accelerate the progression of kidney deterioration. Tricida has
successfully completed a pivotal Phase 3, double-blind,
placebo-controlled trial of TRC101 in patients with CKD and metabolic
acidosis. The results of this Phase 3 trial, along with results from a
successful double-blind, randomized, placebo-controlled Phase 1/2 trial
and an ongoing 40-week extension trial, TRCA-301E, are intended to serve
as the basis for the submission of an NDA for TRC101 under the FDA’s
Accelerated Approval Program.

This press release includes forward-looking statements, including
statements regarding building a successful commercial organization, the
ability of our product candidate to provide benefit to patients, the
advancement of pre-launch planning and strategic commercial efforts, the
continued development and potential commercialization of our product
candidate, the success of our clinical trials, and our ability to submit
an NDA for TRC101 under the FDA's Accelerated Approval Program.
Forward-looking statements involve known and unknown risks,
uncertainties, assumptions and other factors that may cause our actual
results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the
forward-looking statements. These risks and uncertainties include, but
are not limited to, our ability to build a successful commercial
organization; if our product candidate is approved, our ability to
commercialize the product; the expected benefits and efficacy of our
product candidate; the possibility that we may not successfully complete
the required clinical trials required to obtain regulatory approval of
our product candidate; and risks that the FDA would not approve an NDA
under the Accelerated Approval Program. The forward-looking statements
contained in this press release reflect Tricida’s current views with
respect to future events, and Tricida does not undertake and
specifically disclaims any obligation to update any forward-looking
statements.

Contacts

Jackie Cossmon, IRCTricida, Inc.Vice President of Investor
Relations and CommunicationsIR@Tricida.com

Release Summary

Susannah Cantrell to join Tricida as Chief Commercial Officer

Contacts

Jackie Cossmon, IRCTricida, Inc.Vice President of Investor
Relations and CommunicationsIR@Tricida.com